Novo, Aradigm Phase IIb insulin data

NVO and partner ARDM reported that in a 12-week Phase IIb study, the companies' iDMS pulmonary insulin delivered using ARDM's AERx technology was at least as effective as intensified subcutaneous injections of insulin at mealtimes on the primary endpoint of glycemic control in 100 patients with Type II diabetes. ARDM said that intensified injections (which are in addition to patients' normal morning and/or evening injections) are recommended for preventing long-term disease complications. NVO said AERx-iDMS had no safety concerns that would prevent further development. Full data from the trial will be presented next year. ...